HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 278, Issue 48, 48228-48235, November 28, 2003

This Article Full Text Full Text (PDF) All Versions of this Article: 278/48/48228    most recent M304082200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dupré, D. J. Articles by Stankova, J. Search for Related Content PubMed PubMed Citation Articles by Dupré, D. J. Articles by Stankova, J. Social Bookmarking                      What's this?

Trafficking, Ubiquitination, and Down-regulation of the Human Platelet-activating Factor Receptor^*

Denis J. Dupré, Zhangguo Chen, Christian Le Gouill, Caroline Thériault, Jean-Luc Parent, Marek Rola-Pleszczynski, and Jana Stankova

From the Immunology Division, Department of Pediatrics, Rheumatology Division, Department of Medicine, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada

Platelet-activating factor (PAF) is a potent phospholipid mediator involved in various disease states such as allergic asthma, atherosclerosis and psoriasis. The human PAF receptor (PAFR) is a member of the G protein-coupled receptor family. Following PAF stimulation, cells become rapidly desensitized; this refractory state can be maintained for hours and is dependent on PAFR phosphorylation, internalization, and down-regulation. In this report, we characterized ligand-induced, long term PAFR desensitization, and pathways leading to its degradation. Some GPCRs are known to be targeted to proteasomes for degradation while others traffic via the early/late endosomes toward lysosomes. Specific inhibitors of lysosomal proteases and inhibitors of the proteasome were effective in reducing the ligand-induced PAFR down-regulation by 40 and 25%, respectively, indicating the importance of receptor targeting to both lysosomes and proteasomes in long term cell desensitization to PAF. The effects of the proteasome and lysosomal protease inhibitors were additive and, together, completely blocked ligand-induced degradation of PAFR. Using dominant-negative Rab5 and 7 and colocalization of the PAFR with the early endosome autoantigen I (EEAI) or transferrin, we confirmed that ligand-induced PAFR down-regulation was Rab5/7-dependent and involved lysosomal degradation. In addition, we also demonstrated that PAFR was ubiquitinated in an agonist-independent manner. However, a dominant negative ubiquitin ligase (NCbl) reduced PAFR ubiquitination and inhibited ligand-induced but not basal receptor degradation. Our results indicate that PAFR degradation can occur via both the proteasome and lysosomal pathways and ligand-stimulated degradation is ubiquitin-dependent.

Received for publication, April 17, 2003 , and in revised form, August 29, 2003.

^* This work was supported by a studentship (to D. J. D.) and grants (to M. R.-P., J. S., and J.-L. P.) from the Canadian Institutes for Health Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: 3001 12th Ave. N., Dept. of Pediatrics, Immunology Division, Faculty of Medicine, Université de Sherbrooke, Sherbrooke (QC), J1H 5N4, Canada. Tel.: 819-564-5268; Fax: 819-564-5215; E-mail: Jana.Stankova{at}USherbrooke.ca.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J.-G. Li, D. S. Haines, and L.-Y. Liu-Chen Agonist-Promoted Lys63-Linked Polyubiquitination of the Human {kappa}-Opioid Receptor Is Involved in Receptor Down-Regulation Mol. Pharmacol., April 1, 2008; 73(4): 1319 - 1330. [Abstract] [Full Text] [PDF]

				F.-T. Lin, Y.-J. Lai, N. Makarova, G. Tigyi, and W.-C. Lin The Lysophosphatidic Acid 2 Receptor Mediates Down-regulation of Siva-1 to Promote Cell Survival J. Biol. Chem., December 28, 2007; 282(52): 37759 - 37769. [Abstract] [Full Text] [PDF]

				B. L. Wolfe, A. Marchese, and J. Trejo Ubiquitination differentially regulates clathrin-dependent internalization of protease-activated receptor-1 J. Cell Biol., June 21, 2007; 177(5): 905 - 916. [Abstract] [Full Text] [PDF]

				S. K. Shenoy Seven-Transmembrane Receptors and Ubiquitination Circ. Res., April 27, 2007; 100(8): 1142 - 1154. [Abstract] [Full Text] [PDF]

				N. Schwarz, D. Renshaw, S. Kapas, and J. P Hinson Adrenomedullin increases the expression of calcitonin-like receptor and receptor activity modifying protein 2 mRNA in human microvascular endothelial cells. J. Endocrinol., August 1, 2006; 190(2): 505 - 514. [Abstract] [Full Text] [PDF]

				N. J. D. McLaughlin, A. Banerjee, M. R. Kelher, F. Gamboni-Robertson, C. Hamiel, F. R. Sheppard, E. E. Moore, and C. C. Silliman Platelet-Activating Factor-Induced Clathrin-Mediated Endocytosis Requires beta-Arrestin-1 Recruitment and Activation of the p38 MAPK Signalosome at the Plasma Membrane for Actin Bundle Formation. J. Immunol., June 1, 2006; 176(11): 7039 - 7050. [Abstract] [Full Text] [PDF]

				A. P. Comellas, L. A. Dada, E. Lecuona, L. M. Pesce, N. S. Chandel, N. Quesada, G. R. S. Budinger, G. J. Strous, A. Ciechanover, and J. I. Sznajder Hypoxia-Mediated Degradation of Na,K-ATPase via Mitochondrial Reactive Oxygen Species and the Ubiquitin-Conjugating System Circ. Res., May 26, 2006; 98(10): 1314 - 1322. [Abstract] [Full Text] [PDF]

				O. Staub and D. Rotin Role of Ubiquitylation in Cellular Membrane Transport Physiol Rev, April 1, 2006; 86(2): 669 - 707. [Abstract] [Full Text] [PDF]

				J. N. Radin, C. J. Orihuela, G. Murti, C. Guglielmo, P. J. Murray, and E. I. Tuomanen {beta}-Arrestin 1 Participates in Platelet-Activating Factor Receptor-Mediated Endocytosis of Streptococcus pneumoniae Infect. Immun., December 1, 2005; 73(12): 7827 - 7835. [Abstract] [Full Text] [PDF]

				S. Saxena, C. Bucci, J. Weis, and A. Kruttgen The Small GTPase Rab7 Controls the Endosomal Trafficking and Neuritogenic Signaling of the Nerve Growth Factor Receptor TrkA J. Neurosci., November 23, 2005; 25(47): 10930 - 10940. [Abstract] [Full Text] [PDF]

				G. K. Marathe, C. Johnson, S. D. Billings, M. D. Southall, Y. Pei, D. Spandau, R. C. Murphy, G. A. Zimmerman, T. M. McIntyre, and J. B. Travers Ultraviolet B Radiation Generates Platelet-activating Factor-like Phospholipids underlying Cutaneous Damage J. Biol. Chem., October 21, 2005; 280(42): 35448 - 35457. [Abstract] [Full Text] [PDF]

				C. Jacob, G. S. Cottrell, D. Gehringer, F. Schmidlin, E. F. Grady, and N. W. Bunnett c-Cbl Mediates Ubiquitination, Degradation, and Down-regulation of Human Protease-activated Receptor 2 J. Biol. Chem., April 22, 2005; 280(16): 16076 - 16087. [Abstract] [Full Text] [PDF]

				X. Xia, M. Roundtree, A. Merikhi, X. Lu, S. Shentu, and G. LeSage Degradation of the Apical Sodium-dependent Bile Acid Transporter by the Ubiquitin-Proteasome Pathway in Cholangiocytes J. Biol. Chem., October 22, 2004; 279(43): 44931 - 44937. [Abstract] [Full Text] [PDF]